This document summarizes research on circadian rhythms and the effects of exercise, aging, and alcohol consumption. It describes experiments examining how forced and voluntary treadmill running in young and old Syrian hamsters impacts photic and non-photic phase shifting. The research also analyzes how aging, exercise, and alcohol consumption affect activity onset patterns and ethanol intake. The results suggest that exercise can decrease phase shifting and fragmentation in aged hamsters, as well as lower ethanol consumption by providing an alternative reward pathway to running.
Sex, Drugs, and Bad Choices: Modeling Human Decision Making in RatsInsideScientific
To learn more and watch the webinar, go to:
https://insidescientific.com/webinar/sex-drugs-and-bad-choices-modeling-human-decision-making-in-rats/
Nearly every aspect of life involves decisions between options that differ in both their expected rewards and the potential costs (such as delay to reward delivery or risk of harm) that accompany those rewards. The ability to choose adaptively when faced with such decisions is critical for well-being and overall quality of life; however, decision making is often compromised in neuropsychiatric conditions such as substance use disorders, which can prolong and exacerbate their severity and co-morbidities.
During this webinar, Dr. Barry Setlow discusses research in rodent models investigating behavioral and biological mechanisms of cost-benefit decision making. In particular, he focuses on factors (including sex) that contribute to differences in cost-benefit decision making across the population, how variability in decision making is related to substance use, and how substance use can produce long-lasting alterations in decision making. It is hoped that a better understanding of these relationships may lead to new therapeutic approaches for neuropsychiatric conditions characterized by maladaptive decision making.
Key Topics Include:
- Understand how different forms of cost-benefit decision making can be modeled in rats
- Understand the contributions of gonadal hormones to sex differences in cost-benefit decision making
- Understand the lasting effects of chronic cocaine on cost-benefit decision making
Muscle monitoring for optimal rehabilitation & sports performancePetri Lehikoinen
How to use MBody muscle monitoring system to optimize knee rehabilitation and sports performance training.
MEDICA Medicine + Sports Conference 12.-13.11.2014.
Presentation of my doctoral thesis from Karolinska Institutet, dept. of Medical Epidemiology and Biostatistics:
"IF I ONLY HAD A BRAIN - Epidemiological Studies of Parkinson's Disease".
Held on the day of the thesis defence, 10 January 2014.
The full thesis can be downloaded here: http://publications.ki.se/xmlui/handle/10616/41767
Sex, Drugs, and Bad Choices: Modeling Human Decision Making in RatsInsideScientific
To learn more and watch the webinar, go to:
https://insidescientific.com/webinar/sex-drugs-and-bad-choices-modeling-human-decision-making-in-rats/
Nearly every aspect of life involves decisions between options that differ in both their expected rewards and the potential costs (such as delay to reward delivery or risk of harm) that accompany those rewards. The ability to choose adaptively when faced with such decisions is critical for well-being and overall quality of life; however, decision making is often compromised in neuropsychiatric conditions such as substance use disorders, which can prolong and exacerbate their severity and co-morbidities.
During this webinar, Dr. Barry Setlow discusses research in rodent models investigating behavioral and biological mechanisms of cost-benefit decision making. In particular, he focuses on factors (including sex) that contribute to differences in cost-benefit decision making across the population, how variability in decision making is related to substance use, and how substance use can produce long-lasting alterations in decision making. It is hoped that a better understanding of these relationships may lead to new therapeutic approaches for neuropsychiatric conditions characterized by maladaptive decision making.
Key Topics Include:
- Understand how different forms of cost-benefit decision making can be modeled in rats
- Understand the contributions of gonadal hormones to sex differences in cost-benefit decision making
- Understand the lasting effects of chronic cocaine on cost-benefit decision making
Muscle monitoring for optimal rehabilitation & sports performancePetri Lehikoinen
How to use MBody muscle monitoring system to optimize knee rehabilitation and sports performance training.
MEDICA Medicine + Sports Conference 12.-13.11.2014.
Presentation of my doctoral thesis from Karolinska Institutet, dept. of Medical Epidemiology and Biostatistics:
"IF I ONLY HAD A BRAIN - Epidemiological Studies of Parkinson's Disease".
Held on the day of the thesis defence, 10 January 2014.
The full thesis can be downloaded here: http://publications.ki.se/xmlui/handle/10616/41767
Rodent Models of Pharmacotherapy and Chronotherapy for Obesity and Cardiometa...InsideScientific
Join Christopher Axelrod and Sander Kooijman, PhD for a discussion on their research into combatting obesity using various new therapies.
Key Topics Include:
Obesity is a chronic disease with limited treatment options that achieve long term weight control
Systemic mitochondrial uncoupling prevents weight gain without altering food intake and improves glucose metabolism independent of body weight
Mitochondrial-targeted drugs such as BAM15 may have clinical utility in the treatment of obesity and related diseases
Mimicked shift work resulted in obesity in male mice and poor blood glucose clearance in female mice
Understanding the circadian regulation of energy metabolism provides an opportunity to maximize the effectiveness of chronotherapy
Fine Tuning Nutrient Intake Timing for Cardiac HealthInsideScientific
Cardiovascular function changes on a daily basis with potential implications for risk of heart attack and sudden cardiac death. In this webinar, Martin Young, DPhil, will discuss these cardiovascular changes and the potential mechanisms that govern these 24-hour rhythms with a particular focus on circadian clocks. These studies highlight that circadian clocks modulate processes that are critical for normal cardiovascular function, including metabolism. Daily rhythms in metabolism, in turn, influence the manner with which organs (such as the heart) respond to nutrient intake. Dr. Young illustrates the concept that the time of day at which specific macronutrients (such as lipids and proteins) are consumed dramatically impacts the heart. Dr. Young showcases the relevance of these basic science findings to human population studies.
Targeting the hallmarks of aging to reverse age related cardiac dysfunction i...Scintica Instrumentation
Aging sharply increases the risk of cardiovascular disease, the leading cause of death in the United States. Even in individuals without overt cardiovascular disease, aging is associated with increased prevalence of cardiac hypertrophy, impaired diastolic function and reduced myocardial performance. Diastolic dysfunction is a common contributor to heart failure with preserved ejection fraction (HFpEF), which is highly prevalent in the elderly and has no effective treatment. Impaired diastolic function also results in exercise intolerance and in turns contributes to frailty, which is a significant medical and social challenge. Therefore, novel strategies to improve diastolic function in the elderly are urgently needed.
Mitochondrial dysfunction is a hallmark of aging. The heart carries a high energetic demand and the concept that impaired cardiac function is associated with impaired mitochondrial efficiency is well established. However, an important question remains as to whether improving mitochondrial function at late-life can rescue pre-existing age-related cardiac dysfunction. SS-31 peptide, also known as elamipretide, is a mitochondrial targeted peptide that has been shown to reduce mitochondrial oxidative stress and to interact with cardiolipin to modulate cytochrome c function. We recently showed that 8-week SS-31 treatment at late-life can reverse pre-existing diastolic dysfunction in old mice. SS-31 treatment enhances mitochondrial function and normalizes age-related molecular and cellular changes in old murine hearts. Similarly, scavenging mitochondrial reactive oxygen species (ROS) by AAV-mediated mitochondrial-targeted expression of catalase (mCAT) also improves diastolic function in old mice.
Deregulated nutrient sensing is another hallmark of aging. The mechanistic target of rapamycin (mTOR) integrates nutrients and other signals to regulate cell growth and metabolism, and deregulated mTOR signaling has been implicated as a major driver of aging. We have demonstrated that late-life inhibition of mTOR signaling, by caloric restriction (CR) or rapamycin treatment, improves diastolic function and attenuates cardiac hypertrophy in old mice. We discovered that these cardiac benefits are accompanied by proteomic and metabolic remodeling in the heart. Interestingly, rapamycin also induces transient mitochondrial remodeling to improve cardiac mitochondrial metabolism.
Together, these observations support the potentials of interventions targeting hallmarks of aging as therapies for age-related cardiac dysfunction and the concomitant negative physiological consequences in the elderly.
Learning Objectives:
1) Understand the phenotypic changes of cardiac aging and their diagnostic tools in mouse models
2) Discuss the beneficial effects of targeting mitochondrial dysfunction on cardiac aging
3) Discuss the beneficial effects of targeting mTOR signaling on cardiac aging
Weight diabetes and metabolic problems in patients taking atypical antipsycho...Alex J Mitchell
Free slide show on weight gain, diabetes and metabolic problems in those taking atypical antipsychotic medication in schizophrenia, bipolar disorder and related conditions. Image credits retained by original authors. Please give correct acknolwedgements if you present any material from here.
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).
All manuscripts are subject to rapid peer review. Those of high quality (not previously published and not under consideration for publication in another journal) will be published without delay.
This Journal publishes original research work that contributes significantly to further the scientific knowledge in pharmacy.
Myths and legacy of exercisemedicine in chronic diseasesAnn Gates
London Sports and Exercise Medicine Presentation.
December 2015.
Copyright Exercise Works Ltd. All rights reserved.
Contact ann@exercise-works.org for permissions.
Rodent Models of Pharmacotherapy and Chronotherapy for Obesity and Cardiometa...InsideScientific
Join Christopher Axelrod and Sander Kooijman, PhD for a discussion on their research into combatting obesity using various new therapies.
Key Topics Include:
Obesity is a chronic disease with limited treatment options that achieve long term weight control
Systemic mitochondrial uncoupling prevents weight gain without altering food intake and improves glucose metabolism independent of body weight
Mitochondrial-targeted drugs such as BAM15 may have clinical utility in the treatment of obesity and related diseases
Mimicked shift work resulted in obesity in male mice and poor blood glucose clearance in female mice
Understanding the circadian regulation of energy metabolism provides an opportunity to maximize the effectiveness of chronotherapy
Fine Tuning Nutrient Intake Timing for Cardiac HealthInsideScientific
Cardiovascular function changes on a daily basis with potential implications for risk of heart attack and sudden cardiac death. In this webinar, Martin Young, DPhil, will discuss these cardiovascular changes and the potential mechanisms that govern these 24-hour rhythms with a particular focus on circadian clocks. These studies highlight that circadian clocks modulate processes that are critical for normal cardiovascular function, including metabolism. Daily rhythms in metabolism, in turn, influence the manner with which organs (such as the heart) respond to nutrient intake. Dr. Young illustrates the concept that the time of day at which specific macronutrients (such as lipids and proteins) are consumed dramatically impacts the heart. Dr. Young showcases the relevance of these basic science findings to human population studies.
Targeting the hallmarks of aging to reverse age related cardiac dysfunction i...Scintica Instrumentation
Aging sharply increases the risk of cardiovascular disease, the leading cause of death in the United States. Even in individuals without overt cardiovascular disease, aging is associated with increased prevalence of cardiac hypertrophy, impaired diastolic function and reduced myocardial performance. Diastolic dysfunction is a common contributor to heart failure with preserved ejection fraction (HFpEF), which is highly prevalent in the elderly and has no effective treatment. Impaired diastolic function also results in exercise intolerance and in turns contributes to frailty, which is a significant medical and social challenge. Therefore, novel strategies to improve diastolic function in the elderly are urgently needed.
Mitochondrial dysfunction is a hallmark of aging. The heart carries a high energetic demand and the concept that impaired cardiac function is associated with impaired mitochondrial efficiency is well established. However, an important question remains as to whether improving mitochondrial function at late-life can rescue pre-existing age-related cardiac dysfunction. SS-31 peptide, also known as elamipretide, is a mitochondrial targeted peptide that has been shown to reduce mitochondrial oxidative stress and to interact with cardiolipin to modulate cytochrome c function. We recently showed that 8-week SS-31 treatment at late-life can reverse pre-existing diastolic dysfunction in old mice. SS-31 treatment enhances mitochondrial function and normalizes age-related molecular and cellular changes in old murine hearts. Similarly, scavenging mitochondrial reactive oxygen species (ROS) by AAV-mediated mitochondrial-targeted expression of catalase (mCAT) also improves diastolic function in old mice.
Deregulated nutrient sensing is another hallmark of aging. The mechanistic target of rapamycin (mTOR) integrates nutrients and other signals to regulate cell growth and metabolism, and deregulated mTOR signaling has been implicated as a major driver of aging. We have demonstrated that late-life inhibition of mTOR signaling, by caloric restriction (CR) or rapamycin treatment, improves diastolic function and attenuates cardiac hypertrophy in old mice. We discovered that these cardiac benefits are accompanied by proteomic and metabolic remodeling in the heart. Interestingly, rapamycin also induces transient mitochondrial remodeling to improve cardiac mitochondrial metabolism.
Together, these observations support the potentials of interventions targeting hallmarks of aging as therapies for age-related cardiac dysfunction and the concomitant negative physiological consequences in the elderly.
Learning Objectives:
1) Understand the phenotypic changes of cardiac aging and their diagnostic tools in mouse models
2) Discuss the beneficial effects of targeting mitochondrial dysfunction on cardiac aging
3) Discuss the beneficial effects of targeting mTOR signaling on cardiac aging
Weight diabetes and metabolic problems in patients taking atypical antipsycho...Alex J Mitchell
Free slide show on weight gain, diabetes and metabolic problems in those taking atypical antipsychotic medication in schizophrenia, bipolar disorder and related conditions. Image credits retained by original authors. Please give correct acknolwedgements if you present any material from here.
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).
All manuscripts are subject to rapid peer review. Those of high quality (not previously published and not under consideration for publication in another journal) will be published without delay.
This Journal publishes original research work that contributes significantly to further the scientific knowledge in pharmacy.
Myths and legacy of exercisemedicine in chronic diseasesAnn Gates
London Sports and Exercise Medicine Presentation.
December 2015.
Copyright Exercise Works Ltd. All rights reserved.
Contact ann@exercise-works.org for permissions.
9. Death Addiction Late For Work Decreased Ability To Perform ADL’s Increase Stress Increased Addiction Increase in Family, Social, and Family Problems Increased Cost On Society Increase Morbidity And Mortality Rates
10. Females Males Drinking Category* Disease I II III I II III Malignant neoplasms Mouth and oropharynx cancers 1.45 1.85 5.39 1.45 1.85 5.39 Esophagus cancer 1.80 2.38 4.36 1.80 2.38 4.36 Liver cancer 1.45 3.03 3.60 1.45 3.03 3.60 Breast cancer 1.14 1.41 1.59 Under 45 years of age 1.15 1.41 1.46 45 years and over 1.14 1.38 1.62 Other neoplasms 1.10 1.30 1.70 1.10 1.30 1.70 Diabetes mellitus 0.92 0.87 1.13 1.00 0.57 0.73 Neuropsychiatric conditions Epilepsy 1.34 7.22 7.52 1.23 7.52 6.83 Cardiovascular diseases (CVD) Hypertensive disease 1.40 2.00 2.00 1.40 2.00 4.10 Coronary heart disease 0.82 0.83 1.12 0.82 0.83 1.00 Cerebrovascular disease Ischemic stroke 0.52 0.64 1.06 0.94 1.33 1.65 Hemorrhagic stroke 0.59 0.65 7.98 1.27 2.19 2.38 Other CVD causes 1.50 2.20 2.20 1.50 2.20 2.20 Digestive diseases Cirrhosis of the liver 1.26 9.54 9.54 1.26 9.54 9.54
11.
12.
13.
14.
15.
16.
17. Photic Phase Shift Comparison After Four Weeks of Forced Treadmill Running
Review of Neuroendocrinology of ageing (Rehman, H.U.) The D 1 and D 5 receptors are members of the D 1 -like family of dopamine receptors, whereas the D 2 , D 3 and D 4 receptors are members of the D 2 -like family . Activation of D 1 -like family receptors is coupled to the G protein G αs , which subsequently activates adenylyl cyclase , increasing the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP) Activation of D 2 -like family receptors is coupled to the G protein G αi , which directly inhibits the formation of cAMP by inhibiting the enzyme adenylate cyclase.
Review of Neuroendocrinology of ageing (Rehman, H.U.)
*Definition of drinking categories: Category I: for females, 0–19.99 g pure alcohol daily; for males, 0–39.99 g pure alcohol daily Category II: for females, 20–39.99 g pure alcohol daily; for males, 40–59.99 g pure alcohol daily Category III: for females, 40 g or more pure alcohol; for males, 60 g or more pure alcohol. **AF = attributable fraction—that is, the proportion of disease under consideration that is attributable to alcohol. † For liver cirrhosis, a combined estimate was derived for drinking categories II and III. SOURCES: Unless otherwise specified, Gutjahr et al. 2001; for breast cancer and stroke, Ridolfo and Stevenson 2001; for hypertension, Corrao et al. 1999; for CHD, drinking category III, Corrao et al. 2000. NOTE: Relative risk estimates are shown to quantify the effect size of the risk relationships. For example, females in drinking category I have a relative risk of 1.14, compared with female abstainers, of breast cancer. A relative risk of 1.14 corresponds to a 14–percent higher risk. For females in drinking category III, the relative risk is 1.59, or about one and one–half times as large as for female abstainers. The same relationship can also be expressed as a risk increase of 59 percent.
Overall Methods for experiments
Figure 1. Experiment 1A. Representative double-plotted actograms from IR sensors, arrows mark light pulse at ZT 18.5. Light schedule marked by, LD (14:10) and DD on sides of actograms. ( A) Young (6 months) runner, 1 hour of treadmill running shown by blank areas within dark active periods; ( B) Old (19 months) runner, note more consolidated activity compared to the old non-runner; ( C) Young (6 months) control (non-running); ( D) Old (19 months) controls, note fragmentation of activity compared to young animals. (See actogram section in text for complete explanation of actograms). Figure 2. Experiment 1A. The effects of 4 weeks of forced treadmill running at ZT 12 on photic phase shifting in young and old Syrian hamsters. Paired comparison were made between young (6 months of age) non-runners (n=6) and runners (n=6); old (19 months of age) non-runners (n=7) and runners (n=7). Phase shift was the result of a 30-minute light pulse administered at ZT 18.5. A significant age effect was found; young (1.76±0.06), old (2.04±0.06), F (1, 22) =9.41; * p=0.005, (mean±SEM).
Figure 3. Experiment 1A. The effects of forced treadmill speed in relation to H.O.E.S., averaged by week for young and old hamsters. Week 1 and 2, show a familiarization of the hamsters to running on the treadmill with a gradual decrease in H.O.E.S. scores. Week 3 and 4, show a leveling off or plateau of exertion at increasing speeds. (See treadmill section in text for complete explanation). Figure 4. Experiment 1A. Chart shows the triple interaction (time x treatment x age), of the bout analysis performed on the two age groups (young and old) and the treatment (control or running). Data points labeled by (*) are significantly different compared to week 2, young runners, all other groups were non-significant, ( p<0.05 ).
Figure 7. Experiment 1C. Representative actograms, double plotted, showing the effects of 13 weeks of voluntary wheel running on non-photic shifting from the serotonin agonist 8-OH-DPAT administered at CT 6.0. Actograms are arranged by (IR) on the left and (WS) on the right, in pairs; (same animal), except E and F which are spate animals. ( A) Young unlocked IR; ( B) Young unlocked wheel; ( C) Old unlocked IR; ( D) Old unlocked WS ( E ) Young locked IR ( F ) Old locked IR; Red arrows mark 8-OH-DPAT injections, brackets in middle mark LD and DD section, same on all actograms. Figure 8. Experiment 1C. The effects of 13 weeks of wheel running on the non-photic phase shifting of young (6 months) and old (24 months) Syrian hamsters, measured by IR sensor, induced by 8-OH-DPAT injections at CT 6.0. The running groups, young and old, were significantly different, (* p=0.01 ). No significant differences were noted within the young group, non-running IR (n=6) and running IR (n=6) or within the old group of non-running IR (n=6) and running IR (n=6), ( p<0.05 ), (mean±SEM).
Figure 12. Experiment 1D. Effects of aging on non-photic shifting from IP injection of 8-OH-DPAT, on three groups of varying ages; starting age for each group in DD: young, (36.00±0.00 weeks, n=5); middle aged, (49.00±0.89 weeks, n=4) and old, (69.67±0.80 weeks, n=6). Significantly different time points are marked by lines, with p values below each significant point, polynomial trend line fit through all time point (see text for design details), (mean±SEM). Figure 13. Experiment 1D. Wheel revolutions per day, data is grouped into three starting age groups, 6 months, 9 months, and 14 months. Each group is subsequently divided into section of the experimental time line (fig. 8), bars labeled as follows; LD (45 days), Injection 1 in DD (25 Days), Injection 2 in DD (33 Days), Injection 3 in DD (32 Days), Injection 4 in DD (37 Days), (time of each experimental phase). Significant within-group comparisons indicated by letter labeled lines above respective bars; (* p<0.05; ** p<0.01), between-group comparisons marked by, (# p=0.03), (mean±SEM).
12 weeks of wheel access or no wheel access (controls)
Figure 16. Experiment 2. Comparison of IR and WS onsets from animals that were offered free choice of water or EtOH, over a two-month period, data from Experiment 3B. Data is divided by consumption group (EtOH or water), then subdivided by control (first week no EtOH), 1 month (EtOH or water), and 2 month (EtOH or water) time points. WS activity remains constant across both groups for all time points, IR onset under the EtOH gets progressively longer, becoming statistically different from the IR water group at 2 months, (* p=0.01) .
Figure 18. Experiment 3A . The effects of voluntary wheel running, over 30 days, on EtOH consumption (20%), in young Syrian hamsters. The line plot of EtOH consumption over phases (1, 2, and 3) with representative bar graph demonstrating means and significant differences between treatment (running, n=9) and control (non-running, n=9) animals over the three phases. Significant differences in phase 2 and 3 marked by (*and # p<0.05 ). Figure 19. Experiment 3A. The effects of voluntary wheel running over 30 days, on water consumption, in young Syrian hamsters. The line plot of water consumption over phases (1, 2, and 3) with representative bar graph demonstrating means and significant differences between treatment (running, n=9) and control (non-running, n=9) animals over the three phases. No Significant differences were detected between groups ( p<0.05 ). Figure 20. Experiment 3A. The effects of voluntary wheel running, over 30 days, with free access to EtOH (20%), in old Syrian hamsters. The line plot of EtOH consumption over phases (1, 2, and 3) with representative bar graph demonstrating means and significant differences between treatment (running, n=9) and control (non-running, n=9) animals over the three phases. Significant differences between treatment and control in phase 2 (* p<0.05 ). Figure 21. Experiment 3A. The effects of voluntary wheel running over 30 days on water consumption in old Syrian hamsters. The line plot of water consumption over phases (1, 2, and 3) with representative bar graph demonstrating means and significant differences between treatment (running, n=9) and control (non-running, n=9) animals over the three phases. Significant differences between the treatment and control groups in phase 1 and 3 *and #, respectively ( p<0.05 ).